plan of action to improve injection safety within the epi
TRANSCRIPT
Plan of Action
to improve injection Safety
Within the EPI
Overall objective
To ensure the safety of all EPI injections by 2006
Strategies - 1
• Use of AD syringes in all immunization services by the end of 2002.
• Ensure the safe collection, disposal and destruction of used injection equipment using safety boxes and appropriate high temperature incinerators.
• Investigate alternative methods for the safe disposal of used injection equipment.
• Expand training and improve the knowledge of health workers and managers on injection safety.
Strategies - 2
• Establish reliable estimates for equipment requirements, minimum stock levels and effective supply and distribution systems for injection and disposal equipment.
• Institute monitoring and supervision procedures to ensure adequate supplies at all levels and correct practices by health workers.
• Secure the required budget for injection safety including safe disposal and destruction of used equipment.
injection equipment
Autodisable syringe for all EPI injections
Disposable syringe for reconstitution of vaccines
requirements
• The basis for the calculation is based on the planned
number of injections with 10% wastage
• A buffer stock of 25% of the annual routine requirement
is needed to reduce the risk of stock-outs.
• Calculations for safety boxes are based on 100 syringes
per box
Requirements of Safe injection equipment for routine EPI
Item 2003 2004 2005 2006 BCG 2,235,782 1,822,163 1,849,495 1,877,237
AD sysinges 21,566,592 18,052,167 18,525,422 18,822,089
Reconst. Syringes
536,588 544,637 552,806 561,098
Safety boxes 270,162 226,651 232,298 235,991
Training
Training requirements include the following:• The correct use of AD syringes and safety boxes as per
national policy • The appropriate disposal and destruction of used
injection equipment• The accurate calculation of supply requirements and
monitoring of stock• The routine reporting of equipment supply levels to EPI
managers
Advocacy requirements
• A strategy for advocating issues related to injection safety and safe disposal and destruction of used injection equipment is to be developed targeting all levels.
• A specific plan of action for advocacy and communication should be developed by the end of 2003.
Monitoring and indicators
Supervisory visits will include an assessment of injection safety and disposal practices. In addition, surveys when necessary will validate the information from data collected during supervisory visits. Indicators will be based on the following targets:
• 100 % of Provinces with adequate access to appropriate disposal system
• 100 % of Districts with 100% AD use for all EPI vaccines and safe disposal practices
Budget estimates and funding Activity 2003 2004 2005 Incinerators 90,000 150,000 260,000 Training 361,000 381,500 379,500 Mornitoring 60,000 60,000 60,000 Computer network 5,000 50,000 5,000
Review meeting 27,000 27,000 27,000 Evaluation 30,000 45,000 IEC 10,000 20,000 30,000 Equipment 1,457,464 1,259,735 1,292,707 Total 2,010,464 1,978,235 2,099,207
Plan to improve injection safety
within the curative area
Pham Duc Muc
Dept.of Therapy-MOH-SRV
Back ground
- Hos.system consists of 970 hospitals,
approximately 120.000 beds,
- Public hospitals accounts for 98.5%.
- Injection Safety is a major concern
- MOH, NNA,EPI &WHO promote SIGN in VN
Initial achievements
- Pilot study conducted in Hanoi (2001)
- NNA launched a National SI campaign (2001)
- Technical transfer for producing AD products
- Involvement of all concern institutions
The overall objective is to:
Reduce risk to patients, HCWs and public
Strategy to reduce risk to patients
- Eliminate reuse of syringes
- Reduce unnecessary injections
Elimination of reuse
Strategy to reduce risk for HCWs & public
1. Handle of needles properly
2. Use appropriate technology for sharp
waste disposal (safety boxes, needle
removers, & Incinerators
Reduce risk to the HCWs & Public
Plan for the next
1. Production of AD syringes locally & Use of AD
products.
2. Implementation of a nation-wide assessment
3. Development of policies to monitor the practice of
Injection safety
4. Advocacy for SIGN through workshops &
publications
Thank you